How Isomorphic Labs Hunts Hidden Drug Targets

https://spectrum.ieee.org/isomorphic-labs-ai-drug-discovery

Publish Date: 2026-06-11 08:00:01

Over the past decade, artificial intelligence has been heavily promoted as a transformative force in drug discovery, yet, despite substantial investments amounting to billions of dollars, only a limited number of AI-designed medicines have reached patients. This bottleneck occurs partly due to the lengthy drug testing timelines and the inherent difficulties of drug development. Isomorphic Labs, a pioneering Google DeepMind spinoff that leverages groundbreaking protein structure predictive technology, seems to be making significant strides in the field. With major partnerships with pharmaceutical giants Novartis and Eli Lilly, a US $2.1 billion funding raise, and a recent publication detailing its advanced Isomorphic Drug Design Engine (IsoDDE), the company shows promising potential. Isomorphic’s advancements not only focus on predicting protein structures, but also predicting how drugs interact and bind with proteins to identify new disease targets.

Key Points:

– Despite billions of dollars invested, AI has struggled to deliver on its promise in drug discovery due to long drug testing timelines and the inherent complexities of the drug development process.
– Isomorphic Labs, leveraging DeepMind’s advanced protein structure prediction, has made significant headway by forming partnerships with major pharmaceutical companies and securing substantial funding.
– The Isomorphic Drug Design Engine is designed to go beyond basic structure prediction, focusing on identifying “pockets” on proteins where potential drug interactions occur, predicting binding affinity, and modeling a wide range of biomolecular interactions.
– One of its key accomplishments includes discovering previously unknown cryptic protein pockets and correctly predicting ligand binding locations, as highlighted through research on the protein cereblon.
– The system aims to expand the toolset for discovering drugs beyond small molecules, including antibodies, molecular glues, and peptides, thereby providing a versatile approach to tackling a variety of diseases.